Evidence-based medicine and ACE inhibition

Journal of Cardiovascular Pharmacology

Volumn 32, Issue SUPPL. 2, 1998, Pages

  Borghi, Claudio ^a,b   Ambrosioni, Ettore ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ACE inhibitors; Cardiovascular disease; Diabetes mellitus; Evidence based medicine

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; NITRATE; RAMIPRIL; TRANDOLAPRIL; ZOFENOPRIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART REINFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; DIABETES COMPLICATIONS; EVIDENCE-BASED MEDICINE; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0031722745     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800004-00005     Document Type: Conference Paper

References (56)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild-to-moderate hypertension. Arch Intern Med 1984;144:1947-53.
2. Zusman RM. Renin- and non-renin mediated antihypertensive actions of converting enzyme inhibitors. Kidney Int 1984;25:969-83.
3. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316:1429-35.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
5. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
6. The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327: 685-91.
7. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE-inhibitor use in patients with myocardial infarction. Summary of evidences from clinical trials. Circulation 1995;92:3131-7.
8. Borghi C, Ambrosioni E. Clinical aspects of ACE-inhibition in patients with acute myocardial infarction. Cardiavasc Drugs Ther 1996;10:519-25.
9. Navis G, de Zeeuw D, de Jong PE. ACE-inhibitors: panacea for progressive renal disease? Lancet 1997;28:1852-3.
10. Feinstein AR, Horwitz RI. Problems in the "evidence" of "evidence-based medicine." Am J Med 1997;103:529-35.
11. Cochrane Lecture 1997. What evidence do we need for evidence based medicine? J Epidemiol Community Health 1997;51:623-9.
12. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
13. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431-8.
14. Erhardt L, MacLean A, Ilgenfritz L, et al., for the Fosinopril Efficacy/Safety Trial (FEST) study group. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J 1995;16:1892-9.
15. Blumenthal M. Treatment of congestive heart failure. Experience with fosinopril. Am J Hypertens 1997;10:289S-98S.
16. Zannad F, Chati Z, Guest M. Long-term comparison of fosinopril and enalapril in patients with mild to moderate chronic heart failure [Abstract]. Circulation 1997;96(Suppl I):I-612.
17. Sogaard P, Nogaard A, Gotzsche CO, Ravkilde J, Thygesen K. Therapeutic effects of captopril on ischemia and dysfunction of the left ventricle after Q-wave and non-Q-wave myocardial infarction. Am Heart J 1994;127:1-7.
18. Philbin EF, Rocco TA Jr. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic-function. Am Heart J 1997;134(2 Pt 1):188-95.
19. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clin Cardiol 1998;21:103-8.
20. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994;71:584-7.
21. Stafford R, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997;157:2460-4.
22. Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol 1997;59:7-10.
23. Pitt B. ACE-inhibitors in heart failure: prospects and limitations. Cardiovasc Drugs Ther 1997;11:285-90.
24. Jeremy RW, Allman KC, Bautovitch G, Harris PJ. Patterns of ventricular dilatation during the six months after myocardial infarction. J Am Coll Cardiol 1989;13:304-31.
25. Lamas GA. Left ventricular dilatation following myocardial infarction: clinical course and potential for therapy. Cardiology 1989;76: 112-21.
26. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocites in vivo. Cell 1993;75:977-84.
27. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:1161-72.
28. Konstam MA. Angiotension converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure. Eur Heart J 1995;16:59-64.
29. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
30. Ambrosioni E, Borghi C, Magnani B, on behalf of the SMILE Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
31. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
32. Kober L, Torp-Pedersen C, Carlsen JE, et al., for TRACE Study-Group. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) study group. N Engl J Med 1995;333:1670-6.
33. ISIS-4 Collaborative group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial. Lancet 1995;345:669-85.
34. The GISSI-3 Investigators. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
35. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
36. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997;349:1493-7.
37. Borghi C, Marino P, Zardini P, Magnani B, Collatina S, Ambrosioni E. Post acute myocardial infarction. The Fosinopril in Acute Myocardial Infarction Study (FAMIS). Am J Hypertens 1997;10: 247S-54S.
38. Ertl G, Kloner RA, Waine Alexander R, Braunwald E. Limitation of experimental infarct size by angiotensin-converting enzyme inhibitors. Circulation 1982;65:40-8.
39. Przyklenk K, Kloner RA. Angiotensin convening enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am Heart J 1991;121:1319-30.
40. Sogaard P, Gotzsche C-O, Ravkilde J, Thygesen K. Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction. Circulation 1993;87:1093-9.
41. Wright R, Flapan AD, Simpson CC, et al. Effects of captopril on endogenous fibrinolysis in patients with recent myocardial infarction. A double-blind randomised placebo controlled cross-over study [Abstract]. J Am Coll Cardiol 1994;1A:484A.
42. Ridker PM, Gaboury CL, Colin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-73.
43. van Gilst WH, de Graeff PA, de Leeuw MJ, Scholtens E, Wesseling H. Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogeneous nitrovasodilators. J Cardiovasc Pharmacol 1991;18:429-36.
44. Yudkin JS. The emerging role of ACE inhibitors in diabetes: from theory to therapeutic management. J Diabetes Complications. 1996;10:129-32.
45. Zuanetti G, Latini R, Maggioni A, Franzosi MG, Santoro L, Tognoni G. Effect of the ACE-inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Data from the GISSI-3 study. Circulation 1997;96:4239-45.
46. Pitt B. Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis. Eur Heart J 1995;16:49-54.
47. Kowala MC, Recce R, Beyer S, Aberg G. Regression of early atherosclerosis in hyperlipidemic hamster induced by fosinopril and captopril. J Cardiovasc Pharmacol 1995;25:179-86.
48. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 1992;340:1173-8.
49. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary artery disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
50. Lewis EJ, Hunsicker LG, Bain RP, Rohde ED. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
51. Parving HH, Andersen AR, Smidt UM, Swedensen PAA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. BMJ 1992;304:339-43.
52. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
53. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
54. Estacio R, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schipher RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
55. Janka HU, Dirschedl P. Systolic blood pressure as a predictor for cardiovascular diseases in diabetes: a 5-year longitudinal study. Hypertension 1985;7:II-90-4.
56. Koskinen P, Manttari V, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5.